Clinical Trials

Current Studies

The ongoing GAIN Trial, a Phase 2/3 clinical trial of COR388 in Alzheimer’s disease, is fully enrolled and data is expected Q4 2021.  COR388, was previously well tolerated in a Phase 1b trial in healthy subjects and patients with Alzheimer’s disease.  

The GAIN Clinical Trial

The GAIN Trial (GingiPAIN inhibitor for treatment of Alzhimer’s disease) is a Phase 2/3 randomized, double-blind, placebo-controlled study that is assessing the efficacy, safety, and tolerability of two dose levels of COR388 oral capsules in subjects with mild to moderate Alzheimer’s disease.  Randomized participants enter a screening period of up to six weeks, a 48-week treatment period, and a safety follow-up period of an additional six weeks. 

The GAIN Trial has enrolled 643 participants in the United States, France, Spain, Poland, UK and Netherlands. 

Visit for more information.  

Do You or Someone You Love Have Alzheimer’s Disease?